A glycosylated 45,000Mr protein containing Rauscher murine leukemia virus p15 and p12 antigenic sites and tryptic peptides was identified in Rauscher murine leukemia virus-infected cells. This glycoprotein, termed gP45gag, was also shown to contain a single tryptic peptide also present in gPr80gag and its unglycosylated apoprotein precursor Pr75gar, but lacking in Prg5Bag or Pr48ag. The presence of this peptide only in viral precursor proteins containing the so-called leader (L) sequence strongly suggests that gPr45gag is an N-terminal fragment of larger glycosylated gag polyproteins, composed of L sequences in addition to p15 and p12. The kinetics of appearance of radiolabeled gPr45gag and its disappearance during chase-incubation is suggestive of a precursor-like role for this intermediate gene product. An observed 27,000-Mr glycosylated polypeptide, termed gP27gag and containing p15 but not p12, p30, or plO antigenic determinants, is a candidate cleavage product derived from gPr45gag. These observations suggest that gPr459ag and its putative cleavage product gP27gag represent an authentic pathway for intracellular processing of glycosylated core proteins.
The gag gene of murine leukemia virus (MuLV) codes for three primary gene products that have diverse fates. The well-known primary gag gene product, Pr65rar, is the principal precursor polyprotein to the four viral core proteins p30, p15, ppl2, and plO (1, 2, 6, 14) . Our evidence indicates that the cleavage of Pr65sar is facilitated by phosphorylation (15) and by interaction with viral genomic RNA (7) . A second primary gag gene proudct (Pr2009'9aP'1) is synthesized as a joint product of the gag and pol regions. This gag-pol gene product is the precursor to the reverse transcriptase (7, 10, 11) . Stoichiometric considerations and pulse-chase studies conducted in the presence and absence of inhibitors of proteolytic cleavage rule out the possibility that Pr2009'9aP'I is also a major precursor of gag gene products (8) . A third primary gag gene product is a non-glycosylated polypeptide with an apparent molecular weight (Mr) of t Present address: Lawrence Livermore National Laboratory, Livermore, CA 94550. about 75,000 daltons (Pr75905). A Pr755Or is believed to be glycosylated during its synthesis to yield a glycoprotein of approximately 80,000 daltons (gPr800g5) which is glycosylated further, yielding two glycoproteins of 93,000 and 95,000 daltons (3, 19) . These latter proteins were first observed by Tung et al. (21) (2) . The lysate was centrifuged at 10,000 x g for 10 min to remove nuclei and debris. The supernatant was treated with antisera to R-MuLV p30 (lanes B through E) or antisera to RMuLV p15 (lanes J and K). The antigen-antibody complexes were quantitatively precipitated with Staphylococcus aureus (15) . The supernatant from the anti-p30 precipitations were subsequently treated with antibody to RMuLV p12, and the immune complex was again collected by centrifugation (lanes F through I). The immunoprecipitates were denatured by boiling in SDS buffer and fractionated by electrophoresis on a 6 to 12% linear gradient of polyacrylamide in the presence of SDS and mercaptoethanol. Bands were detected in dried gels by autofluorography. Lane A, [3H]leucine marker R-MuLV (20) .
quences as well as p15 and p12 determinants. A 27,000-Mr glycoprotein containing p15 determinants was also detected.
The gag gene products of Rauscher MuLV (RMuLV) were isolated from cytoplasmic extracts of pulse-labeled and chase-incubated infected cell cultures by immunoprecipitation with antip30 and anti-p12 sera (Fig. 1) . Anti-p30 serum precipitated the usual precursor polyproteins from extracts of pulse-labeled cells (Fig. 1, (lanes D, E, and H, I, respectively). Levels of labeled gP93/95gag also decreased drastically in intensity in cells during the 60-min chase (lanes D and H). It is apparent in this experiment that very low levels of gPr459ag can be precipitated by anti-p30 serum (lane B), owing to contaminating antibody to pp12 in this serum. This interpretation is supported by the ability of the anti-p30 serum to precipitate very low levels of pPr259ag from extracts of pulse-labeled cells (lanes C through E). Likewise, the anti-pp12 serum is contaminated with significant levels of antibody to p30. The preclearing of cell extracts with antip30 serum before precipitation with anti-ppl2, however, increases the ratio of gPr459ag to Pr409a9 precipitated by anti-pp12 serum (cf. lanes F and B). Immunoprecipitation of uncleared extracts with an anti-p15 serum which is free from contaminating anti-p30 activity clearly substantiates the p15 content of gPr459ag (lanes J and K) and pPr259ag
The protein band migrating at about 50,000 daltons in this figure (arrow, lane B) was nonspecifically precipitated by various antisera, including antiserum to gp70 and normal rabbit serum (not shown), and is presumed to be actin.
Another minor band, partly overshadowed by the more intense gPr80g'g band, was designated Pr75ag (Fig. 1, (13) .
To determine whether any of the proteins shown in Fig. 1 were glycosylated, we pulselabeled cells with [3H]mannose (3) and immunoprecipitated the viral proteins with monospecific antisera prepared against p15 and plO (Fig. 2) Pr2008ag-P°' (Fig. 2, lane B) . Lower-Mr proteins which were also labeled with [3H]mannose included a 40,000Mr protein, termed gP409ag, which comigrated with PrWag (Fig. 2, lanes A  and B) . Treatment with antiserum to p15 resulted in precipitation of labeled gPr80g'g, Pr200yag-pol.a protein which comigrated with gPr45gag, and a protein termed gP27gag which migrated in the gel only slightly more slowly than did pPr25gag (Fig. 2, lane C) . Neither gPr45gag nor gP27gag were precipitated with antiplO serum (Fig. 2, lane B) . Also, [3H]mannoselabeled gP4Oyag recognized by anti-plO serum (Fig. 2, lane B) was not precipitated with antip15 serum (lane C). Other mannose-containing proteins (Fig. 2, dots) were variably precipitated with both anti-plO and anti-p15 sera and are presumably either degradation products of larger glycosylated gag polyproteins or background host proteins. In another experiment, a similarly labeled extract of cells was precipitated with a mixture of ppl2 and p30 antisera (Fig. 2, lane D) or with antiserum to p15 (lane E). It was apparent that the mannosylated 27,000-Mr protein, gP27 a, was precipitated by antiserum to p15 (Fig. 2 , lane E) but was not precipitated by the mixed ppl2 and p30 antisera (Fig. 2, lane D) . This antibody mixture did, however, precipitate both gPr40gag and gPr459aB. Once again, the previously noted background proteins were observed with either sera. In other studies, nearly identical patterns of [3H]mannose-labeled viral proteins have been obtained from cells infected with R-MuLV which had been biologically cloned free of Rauscher spleen focus-forming virus (data not shown). A glycosylated gagrelated protein of 45,000 Mr has also been detected in cells infected with Moloney murine leukemia virus (data not shown).
We have previously observed that Pr65gag and one of its intermediate cleavage products, Pr25gag, are phosphorylated (15) . The phosphorylation of these precursors presumably occurs at ppl2 sites in the polyprotein molecules. Pr75gag, gPr80gag, and gPr45gag, however, are apparently not phosphorylated (data not shown), even though each of these polyproteins contains p12 sequences. The results shown in Fig. 1 proteins (1, 8, 9) . We have also shown that Pr75Rag made in vitro appears to contain antigenic determinants of all four core proteins (13) . In this study, we compared the peptide maps of gPr80g'g, Pr759aB, and Pr65gag with those of gPr45Rag and Pr409'9 to substantiate the conclusions about the relatedness of these polyproteins reached as a result of immunoprecipitation analyses ( Fig. 1 and 2 ). We prepared [3H]leucine-labeled precursors by means of immunoprecipitation and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and digested the purified polypeptides with trypsin. The digests were fractionated on thin-layer plates in two dimensions (Fig. 3) . Viral proteins purified by chromatography and SDS-polyacrylamide gel electrophoresis (16) were also digested with trypsin, and the peptides were similarly fractionated. The tryptic peptides of each protein were numbered arbitrarily for identification ( Table 1) . As expected, gPr80g'g, Pr75gag , and PrOgag were all found to have very similar peptide maps. All three were found to contain [3H]leucine-labeled peptides in the ppl2, p30, and plO core proteins. We also found that Pr5gag contained a peptide (no. 24) that was not detected in p30, ppl2, p1O, pr758ag, or gPr80gag. Ci/ml) for 20 min, and the cell extracts were precipitated with a mixture of anti-p30 and anti-plO sera. gPr45'0' was precipitated with anti-p12 serum from the supernatants of the extract which had been previously cleared with the anti-plO-anti-p30 sera mixture. The proteins were purified by SDS-polyacrylamide gel electrophoresis as previously described. The [3H]leucine-labeled viral proteins were digested with trypsin as previously described, and the digests were fractionated on thin-layer cellulose plates (11) . The peptide maps of viral p30, as well as of p15, p12 and plO (not shown; see Table 1 ) were also analyzed.
The single p15 leucine-containing peptide characteristic of p15 appears to comigrate with peptide 24 (not shown). It is possible that the p15 peptide is N-terminal in p15 and present in Pr65gag but altered in Pr759ag and gPr8g8ag owing to the presence of L sequence peptides more N-terminal in these precursors (see Table 1 ). It is clear, however, that anti-p1S serum recognizes all three precursors (Fig. 1, lane J) . Also of interest was the finding that Pr759ag and gPr8grag reproducibly contained an additional leucine-labeled tryptic peptide, termed spot 25 (Fig. 3, arrow) , which was not found in Pr65faB, pr40gag, or in any of the viral core proteins. This tryptic peptide was also detected in tyrosinelabeled digests of gPr80fag but not those of tyrosine-labeled Pr659'9 (11) . From immunoprecipitation analyses, we concluded that gPr45gag NOTES 1205 contains p15 and p12 sequences, sugar residues, and, on the basis of size, perhaps other protein sequences. Analysis of the tryptic peptide map of gPr459ag substantiated these conclusions. Furthermore, gPr459ag was shown to contain peptide 25, the single peptide characteristic of both gPr80g'g and its unglycosylated apoprotein, Pr759ag. Thus, gPr45gag appears to be related to gPr80#'g and Pr759a8. In contrast to this, PrWag contained p30 and plO peptides (see Table 1 ) but lacked peptide 25. pr40Wag also contained the p30-specific peptide 17 which was previously noted to be present in PrOgag and Pr75ga9 but absent in gPr8gag.
Several findings indicate that Pr759a9 observed in and isolated from whole cells is a distinct protein not contaminated with gPr80Yag. First, Pr65gag and Pr75gag contained a p30-specific peptide (spot 17; Fig. 3a , c, and e) not found in gPr80gga (Fig. 3d) . Likewise, gPr8Yga8 appeared to contain a peptide (Fig. 3d, spot 23 ) not present in either Pr758ag or Pr65gag or in any of the mature viral proteins (see Table 1 ). Furthermore, two minor spots located above spot 18 in Pr658ag (Fig. 3a) also appear in Pr75gag (Fig. 3c) but are absent from gPr80ga8 (Fig. 3d) . Most significantly, the map of Pr75gag shown in Fig. 3 (panel c) is nearly identical to the map obtained from Pr759ag synthesized in a cell-free translation system or from Pr759a9 synthesized in whole cells in the presence of tunicamycin (data not shown). Peptide 17 in p30 and unglycosylated core-related precursors is thought to be modified by glycosylation in gPr8gag. The new peptide (no. 23 in Fig. 3d ) in gPr80g'g may be glycosylated p30 peptide 17. Consistent with this possibility are the reports that glycosylation of gPr80gag occurs at one location in the p30 region and at a second location in p15 or in the L sequences (4, 17) .
The presence of a common peptide (no. 25) in both unglycosylated Pr759ag and glycosylated gPr80g"a and the absence of this peptide in Pr65.ag strongly suggests that peptide 25 is unique to the L sequence that is also known to be present in both Pr759ag and gPr80gag but absent in Pr659'9. The presence of this same peptide in a newly described intracellular polyprotein, termed gPr459ag, indicates that this polyprotein also contains the L sequence. The fact that gPr459a9 is glycosylated and contains both p15 and p12 antigenic sequences and p12 peptide sequences supports the conclusion that gPr459a9 is a polyprotein representing the Nterminal region of the glycosylated gag gene product. Given the structure of gPr80gag as NH2-L-gp15-p12-gp3O-p1O-COOH, the proposed structure of gPr459ag is NH2-L-gp15-p12-COOH. Kinetics of gPr45'ag disappearance during chase incubation of cells and the comcomitant appearance of a lower-Mr glycoprotein, termed gP279ag, which contains p15 but not p12 sequences suggest specific processing of glycosylated gag gene products in infected cells.
Our results concerning the synthesis of gPr459ag containing p15, p12 and L sequences is supported by the recent observations of others (E. Pillemer and I. Weisman, Stanford University, Stanford, Calif., personal communication) who have prepared a monoclonal antibody that reacts with glycosylated gag polypeptides on the surface of cells infected with and producing AKR MuLV. The antibody does not react with Pr65gag but does react with the apoprotein of glycosylated gag. These results suggest that this antibody is specific for a determinant in the Nterminal leader or L peptide of glycosylated gag polyproteins. Two glycosylated gag polyproteins, as well as the apoprotein, were detected by this antibody on the cell surface of AKR MuLV-infected cells. One glycoprotein is gP93/95gag and the other is a smaller protein containing L, p15, and p12 determinants but lacking p30 and plO determinants. Thus, a protein similar in size and structure to gPr45gag described here has been detected at the surface of AKR virus-infected cells, using antibody specific for the L peptide unique to glycosylated gag polyproteins. The role of gPr45gag, gp279ag, or other glycosylated MuLV core proteins, if any, in retrovirus replication remains to be established.
